1. Introduction {#sec1}
===============

The enzyme 5alpha-reductase (5α-R) exerts a key role in the activation of neuroactive steroids, such as testosterone (T) and progesterone (PROG). Indeed, T and PROG are metabolized by 5α-R into dihydrotestosterone (DHT) and dihydroprogesterone (DHP), respectively. These neuroactive steroids (i.e., steroids synthesized from peripheral glands as well as directly in the nervous system) are then further converted by the action of 3α-hydroxysteroid oxidoreductase (3α-HSOR) or 3β-hydroxysteroid oxidoreductase (3β-HSOR) into further metabolites, such as 5α-androstane-3α,17β-diol (3α-diol) or 5α-androstane-3β,17β-diol (3β-diol) in case of DHT and tetrahydroprogesterone (THP, also known as allopregnanolone) or isopregnanolone in case of DHP. All these neuroactive steroids, together with their precursors (i.e., pregnenolone, PREG, and dehydroepiandrosterone, DHEA) interacting with classical (e.g., progesterone, PR, androgen, AR, and estrogen receptors, ER) and non-classical (e.g. neurotransmitter and membrane steroid receptors) steroid receptors represent important physiological modulators of the nervous function ([@bib38]; [@bib71]). As reported in [Fig. 1](#fig1){ref-type="fig"}, finasteride (e.g., Propecia or Proscar) is an inhibitor of two isoforms of the 5α-R (i.e., type 1 and 2), although it has higher affinity for the type 2 in humans ([@bib30]; [@bib107]). This drug, proved to be highly effective in the control of DHT levels and of the progression of benign prostatic hyperplasia (BPH), was approved for this use in 1992. This inhibitor was then, in 1997, approved for the treatment of androgenetic alopecia (AGA). Finasteride at 1 mg/day has been shown to lead to a significant reduction in the progression of the baldness and to a stimulation of new hair growth ([@bib56]). Dutasteride (e.g., Avodart) inhibits both 5α-R type 1 and 2 ([Fig. 1](#fig1){ref-type="fig"}) with greater potency than finasteride ([@bib32]), and has similar efficacy to this latter drug on BPH symptoms. 5α-R inhibitors have generally been described as well-tolerated and relatively safe drugs; however, recent observations have led to a more critical re-evaluation of these concepts. Indeed, as will be here discussed, 5α-R inhibitors not only induced side effects during the treatment, but, as reported in case of finasteride, they may also persist after drug discontinuation inducing the so called post-finasteride syndrome (PFS).Fig. 1Metabolism of progesterone and testosterone into 5alpha-reduced metabolites and their mechanisms of action: effects of finasteride and dutasteride. AR: androgen receptor; DHP: dihydroprogesterone; DHT: dihydrotestosterone; ERβ: estrogen receptor beta; PR: progesterone receptor; PROG: progesterone; T: testosterone; THP: tetrahydroprogesterone.Fig. 1

1.1. Side effects of 5α-reductase inhibitors and post-finasteride syndrome: what patients tell us {#sec1.1}
-------------------------------------------------------------------------------------------------

Finasteride or dutasteride treatment has been associated with the onset of different side effects. Mainly, the affected domains are related to sexual function. Indeed, sexual adverse events (AEs) in BPH patients treated with finasteride ([@bib10]; [@bib27]; [@bib33]; [@bib66]; [@bib83]; [@bib107]; [@bib115]) or dutasteride ([@bib19]; [@bib22]; [@bib55]; [@bib91]) have been reported. Moreover, observational studies as well as clinical reports indicated similar complaints in male subjects treated with these inhibitors for AGA ([@bib6]; [@bib17]; [@bib56]; [@bib108]). Indeed, analyzing the American Food and Drug Administration Adverse Event Reporting System (FAERS), Gupta and collaborators reported an increased risk to develop sexual dysfunction with finasteride ([@bib41]) or dutasteride ([@bib40]) use in comparison to the baseline risk assessed for all the other drugs. More recently, FAERS database was also queried in order to evaluate which cluster of symptoms have been described after finasteride use at the dose of 1 mg (to treat alopecia) and 5 mg (to treat BPH). Baas and colleagues identified three main areas of AEs, classified as sexual, psychological and physical domains ([@bib3]). In all domains, a significant higher number of cases were present in patients treated with finasteride at the lower dose (1 mg) in comparison to those with the higher dose (5 mg). In particular, within the sexual domain, an increased sexual dysfunction, decreased or loss of libido, disorders of ejaculation, erectile dysfunction, testicular atrophy, orgasmic disorders and hypogonadism were reported by 1 mg finasteride users, while in the psychological domain, the same dose was associated to an increased self-harm, slow cognition, psychological pathology, change in emotional affect and sleep disturbances, compared to the higher dose. Finally, regarding the physical domain, significantly increased reports about skin rush and metabolic abnormalities were indicated by low dose finasteride users. In addition, gynecomastia was more frequently reported by 5 mg finasteride users, although this increase was not statistically significant ([@bib3]). Interestingly, Motofei and colleagues reported differences in sexual complains between right-handed and left-handed subjects taking finasteride, suggesting that lateralization of functions might be relevant in these processes ([@bib78], [@bib79], [@bib80]). In particular, right-handed users presented an overall decreased International Index of Erectile Function (IIEF) score compared to the left-handed users, that have, on the other side, an improved orgasmic function compared to the right-handed finasteride users ([@bib78], [@bib79], [@bib80]). In contrast with these findings, Haber and collaborators reported no sexual dysfunction associated to finasteride treatment for alopecia in a single-centre, controlled study of 762 subjects ([@bib42]). In addition, other reports, including randomized studies, showed no incidence of sexual impairment after finasteride use ([@bib65]; [@bib81]; [@bib106], [@bib105]).

Overall, these results indicate no consensus with respect to the presence of sexual side effects during treatment with 5α-R inhibitors.

However, recent observations also demonstrated that, in case of AGA, side effects associated with finasteride may also persist despite the drug suspension (i.e., inducing the PFS). Indeed, Irwig and Kolukula interviewed 71 subjects who reported sexual dysfunction despite they stopped finasteride use by at least three months ([@bib52]). They described low libido, erectile dysfunction, decreased arousal and difficulty in achieving an orgasm ([@bib52]). Interestingly, these adverse events did not resolve in the majority of subjects after 9 and 16 months of withdrawal from the drug ([@bib50]). Another report collected 131 web-based surveys of patients lamenting new symptoms onset after finasteride use. Subjects were recruited from those seeking medical help after treatment or visiting [Propeciahelp.com](http://Propeciahelp.com){#intref0010} website ([@bib35]). Authors divided symptoms collected from patients in five categories: physical, sexual libido, disorder of penis and testes, cognitive disorders and psychological disorders. From each category, the higher percentage of cases regarded: gynecomastia (70% of cases in physical category), decreased sex drive (93% of cases in sexual libido category), diminished semen volume and force (82% of cases in disorder of penis and testes category), mental cloudiness or brain fog (75% of cases in cognitive disorders category) and elevated anxiety (74% of cases in psychological disorders category) ([@bib35]). This survey also highlighted the high number of subjects reporting suicidal ideation (63%), due to the negative thoughts and the inability to live a life with such symptoms ([@bib35]). This latter result was in line with previous findings ([@bib49]).

Observations based on a recent questionnaire-based survey performed in 54 PFS patients have been also published ([@bib36]). As shown, 22% of patients reported lack of connection between the brain and penis during treatment, and this percentage increased to 59% at interview time (i.e., at least three months after finasteride discontinuation). This side effect was not reported by the patients before the finasteride treatment. Similarly, the loss of libido and sex drive was reported in 24% of the patients during treatment and increased to 56% at interview time. This side effect was reported in 4% of patients before the treatment. Difficulty in achieving an erection was reported in 17% of patients during inhibitor administration and increased to 61% at interview time. Finally, genital numbness or paresthesia was reported in 17% of patients during treatment and increased to 37% of cases at interview time ([@bib36]). Beside sexual problems, PFS patients also reported psychological complaints (such as decreased self-confidence, irritability or easily flying into a rage, nervousness, agitation, inner restlessness, depression, hopelessness, feelings of worthlessness, suicidal thoughts, anxiety, panic attacks, sleep problems), muscular problems (tics, muscle spasms and fasciculation, tremors, involuntary muscle tension and contraction, chronic fatigue, weakness, ataxia, joint pain and muscular ache), physical alterations (dizziness, headache, migraine, head pressure, decreased body temperature) and cognitive complains (decreased initiative and difficulty in concentration, mental confusion, forgetfulness or loss of short-term memory, losing train of thought or reasoning, slurred speech or stumbling over words) ([@bib73]).

"Propeciahelp.com" forum has been also considered as a source. Indeed, Walf and colleagues analyzed 224 discussions on this web site and collected self-reported symptoms of PFS patients ([@bib112]). The symptoms were divided into four categories: anti-androgenic effects (such as demasculinizing events consequent to DHT deprivation on sexual organs), estrogenic effects (i.e., feminizing features related to the increased aromatization of testosterone), central/brain effects (linked to the alteration of neurosteroid synthesis and metabolism or to thromboembolitic events) and, finally, nonspecific/severe AEs (collecting other severe effects that could not be classified in the above categories but are considered serious) ([@bib112]). The analysis indicated antiandrogenic effects in the 32%, central effects in the 30%, estrogenic effects in the 19%, and nonspecific/severe AEs in the 5% of cases ([@bib112]).

Persistent sexual side effects possibly due to finasteride treatment have been also analyzed by Healy and colleagues based on the self-reported alerts into the [RxISK.org](http://RxISK.org){#intref0015} website (i.e., an independent drug safety website aiming to collect data on all drug-related AEs) ([@bib44]). A total of 24 male subjects completed the report indicating different symptoms related to sexual functions that persisted after finasteride use. In line with previous reports, 92% of patients claimed erectile dysfunction and loss of libido, 44% genital anesthesia and 32% watery ejaculation and testicular atrophy. In this survey, other infrequent symptoms, such as reduced sense of taste (8%) and of smell (4%), were reported ([@bib44]).

Criticism about the existence of PFS has been also raised. In particular, subject selection in the study design, lack of adequate control groups, possible nocebo effect and the use of retrospective questionnaires may introduce important biases, leading to poor quality of the studies performed ([@bib3]; [@bib42]; [@bib76]).

Nevertheless, it is important to highlight that the so called PFS is a rare condition, that could be not adequately investigated in larger cohort studies. In particular, many of these studies lack of long follow-up of patients, and specific symptoms (e.g., sexual dysfunction or psychological problems) may not be investigated in detail ([@bib6]). On the other hand, objective measurements and deeper clinical assessments are imperative to describe PFS symptomatology.

1.2. What has been so far clinically demonstrated about the existence of PFS {#sec1.2}
----------------------------------------------------------------------------

As mentioned in section [2.1](#sec2){ref-type="sec"}, the observations present in literature are mainly based on symptoms self-reported by patients. Indeed, only few papers have rigorously investigated these aspects so far ([Fig. 2](#fig2){ref-type="fig"}). In this context, one of the markers taken in consideration has been the levels of neuroactive steroids in PFS patients. The rational was based on the following reasons: 1) finasteride is able to block a fundamental step in the activation of neuroactive steroids (i.e., 5α-R) ([@bib30]; [@bib107]); 2) finasteride in AGA patients induced, during treatment, changes in the plasma levels of neuroactive steroids (i.e., decrease in DHT and increase in T and androstenedione) ([@bib26]); 3) neuroactive steroids are important key regulators of the nervous functions ([@bib38]; [@bib71]); 4) some neuroactive steroids, like for instance THP, isopregnanolone and 3α-diol are able to modulate GABA-A receptors ([@bib60]); 5) altered levels in plasma and cerebrospinal fluid (CSF) of GABA as well as of neuroactive steroids are associated with depression in several human studies ([@bib70], [@bib71]; [@bib123]). In addition, a subset of post-finasteride patients with persistent symptomatology showed a decline in their alcohol consumption ([@bib51]). This is very interesting, because a relationship between GABAergic neuroactive steroids and ethanol consumption is well ascertained ([@bib59]). On the basis of this rationale, in three different studies based on three ([@bib68]), seven ([@bib12]) and fourteen ([@bib73]) PFS patients, the plasma and CSF levels of different neuroactive steroids (i.e., PREG, DHEA, PROG and its metabolites, T and its metabolites) have been assessed by liquid chromatography-tandem mass spectrometry. Data obtained indicate that finasteride treatment has broad consequences on the levels of these molecules in plasma and particularly in CSF ([@bib12]; [@bib68], [@bib73]). Thus, finasteride treatment did not only affect the 5α-reduced metabolites of PROG and T. Indeed, as observed in the study with the larger group of patients, lower levels of PREG, PROG, DHP, DHT and 17β-E and higher levels DHEA, T and 3α-diol were reported in the CSF of PFS patients in comparison with those observed in healthy patients ([@bib73]). The results obtained in this latter study showed small differences in comparison to the previous ones ([@bib12]; [@bib68]). This, together with the presence of a heterogeneous symptomatology, suggests that PFS patients are not a homogenous pathological group. Interestingly, the pattern in plasma did not exactly reflect what observed in CSF. For instance, at variance to what observed in CSF, the plasma levels of PREG were significantly increased and those of PROG and T metabolites, such as DHT, 3α-diol and 17β-E, were unaffected. In addition, the levels of THP that were unaffected in CSF, showed a significant decreased in plasma. These findings were not surprising because, as demonstrated in various physiological or pathological experimental models, neuroactive steroid changes occurring in plasma did not reflect exactly what occurs in CSF and in the nervous system ([@bib13]; [@bib70], [@bib71]). As demonstrated, not only neuroactive steroid levels themselves but also their mechanisms of action may be altered by finasteride. For instance, an upregulation of AR occurred in the prostate of patients treated with finasteride for BPH ([@bib47]) as well as in the prepuce of AGA patients showing persistent side effects (i.e., PFS patients) ([@bib24]). In addition, two polymorphisms in AR gene, (CAG) rs4045402 and (GGN) rs318869, have been reported to be more frequent among AGA and PFS patients ([@bib15]). As further demonstrated, short and/or long (CAG)n and (GGN)n repeats in the AR gene have also different frequencies according to the symptomatology reported by PFS patients ([@bib14]).Fig. 2Clinical features reported in patients affected by post-finasteride syndrome. For details, see text. AR: androgen receptor; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging; SRD5A2: 5 alpha reductase type 2 gene.Fig. 2

Epigenetic modifications seem to be also involved ([@bib69]). Indeed, as recently demonstrated, methylation analysis of the promoter genes coding for type 1 (i.e., *SRD5A1*) and type 2 (i.e., *SRD5A2*) 5α-R performed in plasma and CSF of 16 PFS patients, indicated that *SRD5A2* promoter was more frequently methylated in CSF of PFS patients compared to healthy controls (56.3% *versus* 7.7%). Importantly, this is a tissue-specific methylation. Indeed, *SRD5A2* promoter methylation has not been observed in plasma. Interestingly, both in plasma and CSF, *SRD5A1* promoter was not methylated ([@bib69]).

Basaria and coworkers ([@bib5]) observed impaired sexual function, assessed by IIEF and Male Sexual Health Questionnaire, in 25 PFS patients. These observations were confirmed in another study performed in 16 PFS patients, reporting that 10 of them showed a severe erectile dysfunction, while 6 patients a mild-moderate one ([@bib73]). As demonstrated by ultrasonography scan, erectile dysfunction in these patients was not associated with altered testicular volume or alterations in ejaculatory ducts. Interestingly, an objective evidence of neuropathy involving the peripheral neurogenic control of erection was reported. Indeed, abnormal somatosensory evoked potentials of the pudendal nerve were observed in 25% of these PFS patients ([@bib73]).

Depressive symptomatology is related with alteration in neuroactive steroid levels ([@bib70], [@bib71]; [@bib123]). In addition, the expression levels of 5α-R type 1 enzyme are downregulated in prefrontal cortex Brodmamn\'s area 9 of depressed patients ([@bib1]). Indeed, as reported in two different studies, using PHQ-9 depression scale, Beck Depression Inventory and Hamilton Depression Scale 17 ([@bib5]) or K-10, Mini-International Neuropsychiatric Interview and Beck Depression and Anxiety Inventories ([@bib73]), the presence of DSM-IV major depressive disorder was confirmed in PFS patients. Interestingly, functional MRI in PFS patients confirmed abnormalities in brain regions implicated in depression and sexual arousal, such as nucleus accumbens and prefrontal cortex ([@bib5]). In addition, further studies showed that more than half of the 150 PFS patients considered had a pre-existing medically confirmed psychiatric diagnosis ([@bib34]; [@bib35]).

1.3. What experimental models tell us {#sec1.3}
-------------------------------------

As mentioned in sections [2.1 and 2.2](#sec2){ref-type="sec"}, observations so far obtained in AGA patients have indicated that both during finasteride treatment ([@bib26]) and after its suspension (i.e., in PFS patients) ([@bib12]; [@bib68], [@bib73]) the levels of neuroactive steroids are affected. Observations obtained in male adult rats have confirmed these observations ([@bib37]). Interestingly, 20 days of finasteride treatment and its withdrawal (i.e., one month of suspension), not only alter the levels of neuroactive steroids in plasma and CSF, but also those in the central nervous system areas such as cerebral cortex, cerebellum and hippocampus ([@bib37]). Importantly, finasteride treatment differently influenced the neuroactive steroid levels in the brain areas considered. For instance, PROG levels were increased in the hippocampus but not in the cerebral cortex and cerebellum. In addition, levels of isopregnanolone and 3α-diol were increased and decreased respectively in the cerebellum; these changes did not occur in the cerebral cortex and hippocampus ([@bib37]). At the withdrawal, some of the changes observed persisted, such as the increase in DHP in the cerebellum, and new changes occurred, such as an increase and a decrease of PREG levels in the cerebellum and hippocampus, respectively and a decrease of THP in the cerebral cortex. In addition, T levels were increased while the levels of its metabolite, DHT, were decreased in the cerebellum ([@bib37]) ([Fig. 3](#fig3){ref-type="fig"}).Fig. 3Side effects of treatment with 5 alpha-reductase inhibitors in experimental models. For details, see text.Fig. 3

Moreover, not only the levels of neuroactive steroids but also the expression of their receptors, are altered by finasteride treatment in the brain areas considered. Indeed, an upregulation of AR in rat cerebral cortex occurred after the chronic treatment as well as at the withdrawal ([@bib37]). This is particularly interesting, because it indicates that the expression of this receptor is not only affected in the periphery, as observed in AGA patients ([@bib24]), but also in the nervous system. In addition, the expression levels of one GABA-A subunit, such as the beta 3, were also upregulated in the cerebellum after finasteride treatment ([@bib37]). At the withdrawal, an upregulation of the isoform alpha and a downregulation of the isoform beta of ER were reported in the cerebral cortex. In addition, the expression of alpha 4 and beta 3 subunits of GABA-A receptors was downregulated in the cerebral cortex ([@bib37]).

As mentioned above, depressive symptomatology has been reported in PFS patients ([@bib5]; [@bib73]). Concerning observations in animal models, controversial results have been collected so far. For instance, finasteride treatment in adult male rat showed an increased time of immobility in forced swim test. This effect occurred after one month of withdrawal, but not immediately after the treatment ([@bib25]) ([Fig. 3](#fig3){ref-type="fig"}). On the contrary, as recently reported in adult male rats by forced swim test, finasteride administration induces, immediately after the treatment, a depression-like phenotype ([@bib95]). Differences in the experimental protocol, like for instance animal strain (Sprague-Dawley rat vs Wistar rat), finasteride dose (i.e., 3 mg/kg vs 30 mg/kg), time schedule (20 days of treatment vs 6 days) might be responsible for this discrepancy of effect.

Interestingly, anhedonia or decreased pleasure-seeking behavior have been also explored by Sasibhushana and colleagues ([@bib95]). Results obtained by the splash test indicate that finasteride treatment decreased the grooming duration and increased the latency to groom, which indicates that the drug affected the motivational behavior in a negative way ([@bib95]).

Not only alterations in neuroactive steroid levels ([@bib70], [@bib71]; [@bib123]) but also changes in hippocampal neurogenesis have been related with depressive-like behaviors ([@bib94]; [@bib99]). Altered hippocampal morphology and reduced hippocampal neurogenesis have been also reported in depressed patients ([@bib45]; [@bib100]). Interestingly, 6 days of finasteride administration in male C57BL/6N mice were able to decrease the hippocampal neurogenesis ([@bib92]; [@bib93]). Recent observations in a rat model have shown that 20 days of treatment induced a decrease of granule cell density in the granular layer of the dentate gyrus in rats showing depressive-like behavior one month after the end of finasteride treatment ([@bib25]) ([Fig. 3](#fig3){ref-type="fig"}).

In humans and experimental models, depression has been demonstrated to be associated with neuroinflammation ([@bib119]). Treatment with finasteride also affects this parameter ([Fig. 3](#fig3){ref-type="fig"}). Indeed, a significant increase in the number of astrocytes (i.e., cellular mediators of the inflammatory response) in the hilus of the dentate gyrus has been demonstrated one month after the end of the finasteride treatment ([@bib25]). This effect might be ascribed to the elevated levels of DHP observed one month after the end of the finasteride treatment in male rat hippocampus ([@bib37]). Indeed, in other experimental models, DHP has been demonstrated to increase GFAP gene expression in astrocytes ([@bib72]). Reactive gliosis is associated with increased levels of proinflammatory molecules in the brain ([@bib46]; [@bib113]). In agreement, finasteride treatment increased, immediately after the treatment, the expression of TNF-α in male rat hippocampus and, at the withdrawal, that of IL-1β ([@bib25]). It is important to note that both cytokines are increased in plasma of depressed patients and in the brain of animal models for depression ([@bib16]; [@bib63]; [@bib104]; [@bib113]). Dysregulation of the dopamine system may also contribute to major depressive disorders ([@bib7]; [@bib28]; [@bib39]). Therefore, in this context it is important to recall that androgens regulate the dopaminergic system in the brain ([@bib21]; [@bib58]; [@bib75]). Interestingly, finasteride treatment (25 and 50 mg/kg for 14 days) inhibited open-field behaviors and reduced contents of dopamine and its metabolites in central nervous system ([@bib62]). In addition, finasteride treatment was also able to impair the signaling of dopamine ([@bib23]; [@bib31]).

Androgens are also involved in the physiological regulation of erection. Few preclinical observations have been obtained on the effects exerted by 5α-R inhibitors. For instance, a 5α-R inhibitor, such as 17 beta-testosterone carboxylic acid, significantly weakened the stimulatory effect exerted by T propionate on erection in castrated rats, but not the mating behavior ([@bib9]). Similarly, another study performed with finasteride in castrated rats also reported a reduction of erectile response, although receiving T replacement ([@bib86]). Pinsky and colleagues demonstrated a detrimental effect of dutasteride on erectile function as well as in the gene expression of nitric oxide synthase in intact adult male rats ([@bib88]). In addition, another study demonstrated that oral administration of finasteride for one month was not able to affect the erectile response to electric stimulation of the cavernous nerve, but resulted in a loss of the weight of the corpus cavernosum ([@bib122]). Furthermore, a further study performed in Wistar--Kyoto adult rats showed that treatment with finasteride or dutasteride reduced cross-sectional penile area ([@bib20]). In addition, in the same study, dutasteride, but not finasteride treatment, reduced smooth muscle in the corpus cavernosum ([@bib20]). To our knowledge, only one preclinical study has explored so far possible persistent erectile dysfunction induced by 5α-R inhibitors ([@bib101]). In particular, it seems that the recovery from erectile dysfunction depends on the duration of treatment. Indeed, after two weeks of withdrawal the erectile dysfunction persisted in rats treated with dutasteride for more than 8-weeks, but not for 4-weeks ([@bib101]) ([Fig. 3](#fig3){ref-type="fig"}). In this context, it is also important to recall that, dopamine, a neurotransmitter that, as reported above, is affected by finasteride treatment ([@bib23]; [@bib31]; [@bib62]), also modulates male sexual behavior in humans as well as in animal models ([@bib87]; [@bib114]).

Finally, as recently demonstrated, finasteride treatment also leads to kidney damage ([@bib4]) as well as alterations in gut microbiota ([@bib25]). Indeed, an experimental study performed on sexually mature male Wistar rats, confirmed not only that finasteride treatment altered the steroid hormone levels in plasma, but also the expression of AR and intracellular junction proteins in the kidney was impaired ([Fig. 3](#fig3){ref-type="fig"}). These alterations are associated with an altered cell apoptosis/proliferation ratio, and linked to lymphocyte infiltration and to an increase of IL-6 ([@bib4]). Finasteride treatment is also able to affect, not only immediately after treatment but also after one month of discontinuation of the drug, the gut microbiota composition ([@bib25]). Indeed, immediately after drug treatment an increase in *Bacteroidetes phylum* as well as in *Prevotellaceae* family was reported; after discontinuation of the finasteride, a decrease in *Ruminococcaceae* family, *Oscillospira* and *Lachnospira* genus was observed ([@bib25]) ([Fig. 3](#fig3){ref-type="fig"}). Changes in gut microbiota could be ascribed to different factors, such as changes induced by finasteride in plasma and/or brain neuroactive steroid levels ([@bib37]). Indeed, gonadectomy and hormone replacement have a clear effect on gut bacteria in rodents ([@bib29]; [@bib43]; [@bib53]; [@bib77]; [@bib85]; [@bib102]; [@bib121]). For instance, *Ruminococcaceae* are significantly affected by orchidectomy in mice ([@bib85]). In addition, the existence of a gut microbiota-brain axis has been proposed ([@bib61]; [@bib67]; [@bib97]). On the other hand, although steroidogenesis has not been evaluated in detail in gut microbiota, intestinal epithelial cells seem to be able to synthesize glucocorticoids ([@bib18]) and microbial species, like for instance *Clostridium scindens*, converts glucocorticoids into androgens ([@bib90]). Thus, an alternative possibility is a direct action of finasteride on gut microbiota. Results obtained on rat gut microbiota population after finasteride treatment are also interesting since very similar changes have been observed in patients with major depressive disorder ([@bib54]; [@bib64]; [@bib82]) as well as in animal models of depression. For instance, rats with depressive-like behavior show an increase in *Bacteroidetes* ([@bib120]).

1.4. What about finasteride therapy and PFS in women? {#sec1.4}
-----------------------------------------------------

Finasteride has been approved by the US FDA for the treatment of alopecia only in male subjects. However, this drug is increasingly used also in women to treat female pattern hair loss (FPHL) and frontal fibrosing alopecia (FFA) ([@bib11]; [@bib48]).

With particular regard to female alopecia, finasteride is considered both effective ([@bib8]; [@bib84]; [@bib116]) and ineffective ([@bib57]; [@bib89]; [@bib110]; [@bib111]). Moreover, indications for finasteride dosage are confusing. Indeed, studies reporting dose of 1 mg, 1.25 mg, 2.5 mg or 5 mg have been published ([@bib8]; [@bib57]; [@bib74]; [@bib89]).

Also in case of female finasteride users, side effects have been reported during treatment. In particular, Wu and colleagues discussed information about finasteride side effects in female patients, collected in the FAERS database ([@bib117]). The top ten AEs reported were: abortion induction, abortion spontaneous, paternal drug affecting fetus, uterine cervix stenosis, menstruation irregularity, menorrhagia, endometrial hypertrophy, phalangeal agenesis, fatigue and arthritis ([@bib117]). Regarding the adverse events on reproductive features, it is important to recall that finasteride is forbidden in pregnant women, therefore, careful contraception is strongly suggested during finasteride treatment.

Other data described, in women treated for alopecia with 5 mg of finasteride, headache, menstrual irregularities, dizziness and increased body hair growth as the most common complaints ([@bib98]; [@bib109]; [@bib118]). Moreover, decreased libido and gastrointestinal discomfort were also described ([@bib98]; [@bib103]; [@bib109]; [@bib118]). A drug-gene network analysis, in patients treated with finasteride, also revealed that "oocyte meiosis" and "progesterone-mediated oocyte maturation" pathways were affected by finasteride treatment ([@bib117]). Few studies evaluated finasteride toxicity in female animal models. Of note, a paper by Alkahtane and collaborators showed altered serum biochemical parameters (e.g., alkaline phosphatase, cholesterol, glucose), increased DNA damage and histological abnormalities in the liver, spleen, kidney and heart of female Swiss albino mice treated with finasteride (0.5 or 1.5 mg/kg/day) ([@bib2]) ([Fig. 3](#fig3){ref-type="fig"}).

Also in female patients, criticism about the possible side effects induced by 5α-R inhibitors has been raised. Indeed, in FPHL and FFA, very few side effects or AEs related to sexual function in women treated with finasteride have been reported ([@bib96]). In agreement, Mervis and collaborators, by analyzing 24 clinical studies (a total of 521 women), reported a decrease of libido or headache in 1.9% and 2.2% of cases respectively ([@bib74]). All these side-effects were present during the finasteride treatment, but not after its suspension, suggesting, on the basis of the literature available so far, that PFS is present only in males.

2. Conclusions and perspectives {#sec2}
===============================

As here reported, finasteride or dutasteride treatment in male is associated with the onset of different side effects (i.e., mainly on sexual functions as well as on mood, even if other complaints have been described). In agreement, rodent models treated with these drugs present different degree of alterations in sexual function and mood regulation. Interestingly, some of these side effects has been reported also in female. On the other hand, reports observing no adverse events have been published as well, raising doubts about the real presence of such symptoms and the quality of the studies performed so far.

Another important point, recently emerged, is the persistence of these side effects after withdrawal of the therapy. This condition, named as PFS, seems to be present in male patients, with an incidence on the total population that is still unclear. Results obtained in animal models confirm the presence of long-term effects of finasteride or dutasteride treatment on sexual function and mood, such as depression and anxiety. However, also in this case, concerns about PFS existence have been raised. Overall, these data indicate the urgent need to high quality clinical trials, with long-term follow up, specifically addressing sexual function and mood disorders. In addition, it is imperative to study in detail the molecular mechanisms that cause this condition, trying to identify a possible genetic predisposition, in order to limit the burden of PFS. Finally, therapeutic strategies, like for instance neuroactive steroid treatment, able to relief or to cure this condition are also urgently needed.
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